GSK's Walmsley Focused On Upcoming Launches Amid 'Uncertain' Times
Executive Summary
New CEO confirmed GSK's commitment to maintaining its three business unit structure ‒ "as long as all three businesses continue to perform competitively" ‒ as she chaired her first quarterly results presentation at the helm of the big pharma.
You may also be interested in...
GSK Shingrix Shingles Vaccine Seen Displacing Zostavax After US FDA Approval
US FDA OK for its two-shot shingles regime gives GSK a likely blockbuster with a clear best-in-class profile.
Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.